Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity

Klerk, Timothy A de; Park, D Y; Biswas, Susmito

doi:10.1038/eye.2013.148

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a phenomenon typically occurs quite late in the disease course and can progress to retinal detachment without treatment. Therefore, a prolonged follow-up for late peripheral retinal changes and reactivation appears to be mandatory until complete vascularization is achieved or laser ablation of avascular peripheral retina is performed (20)(21)(22).…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

et al. 2016

View full text Add to dashboard Cite

Background/aim: To evaluate refractive and strabismic results and the efficacy of intravitreal bevacizumab in retinopathy of prematurity (ROP) ineligible for laser therapy. Materials and methods:Thirty-nine eyes of 20 consecutive infants with high-risk prethreshold ROP (11 infants with Zone I and 9 infants with Zone II disease) who were ineligible for laser therapy due to systemic and/or ocular conditions were treated with intravitreal bevacizumab. Recurrent retinopathy was treated with laser ablation. The final follow-up examination was performed at 29.8 ± 6.0 months of corrected age.Results: All eyes responded to the initial treatment with intravitreal bevacizumab. ROP recurred in 8 eyes (36%) with initial Zone I disease and in only 2 eyes (11%) with initial Zone II disease, which were successfully treated with laser ablation. No eye developed myopia higher than 5.0 diopters. At 2.5 years, the Zone I eyes that had received laser treatment appeared to be more myopic than the Zone I eyes treated only with intravitreal bevacizumab (P = 0.038). A tendency for a higher incidence of strabismus after additional laser therapy was also noted, but was not significant (P = 0.22). Conclusion:Avoidance or even deferral of laser ablation with intravitreal bevacizumab may lead to less myopization in ROP compared with conventional laser treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

et al. 2016

View full text Add to dashboard Cite

show abstract

Bevacizumab

2018

Reactions Weekly

View full text Add to dashboard Cite

A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity

et al. 2015

View full text Add to dashboard Cite

IntroductionLaser photocoagulation is the current gold standard treatment for proliferative retinopathy of prematurity (ROP). However, it permanently reduces the visual field and might induce myopia. Vascular endothelial growth factor (VEGF) inhibitors for the treatment of ROP may enable continuing vascularization of the retina, potentially allowing the preservation of the visual field. However, for their use in infants concern remains. This meta-analysis explores the safety of VEGF inhibitors.MethodsThe Ovid Interface was used to perform a systematic review of the literature in the databases PubMed, EMBASE and the Cochrane Library.ResultsThis meta-analysis included 24 original reports (including 1.457 eyes) on VEGF inhibitor treatment for ROP. The trials were solely observational except for one randomized and two case-control studies. We estimated a 6-month risk of retreatment per eye of 2.8%, and a 6-month risk of ocular complication without the need of retreatment of 1.6% per eye. Systemic complications were only reported as isolated incidents.DiscussionVEGF inhibitors seem to be associated with low recurrence rates and ocular complication rates. They may have the benefit of potentially allowing the preservation of visual field and lower rates of myopia. Due to the lack of data, the risk of systemic side effects cannot be assessed.

show abstract

Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity

Cited by 4 publications

References 5 publications

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

Bevacizumab

A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity

Contact Info

Product

Resources

About